---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-24-237665"
form_type: "8-K"
ticker: "WVE"
cik: "0001631574"
company_name: "Wave Life Sciences Ltd."
filed_at: "2024-10-15T23:59:59+00:00"
generated_at: "2026-05-30T14:36:21.506361+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Takeda terminates HTT option; Wave Life Sciences regains full rights to WVE-003 Huntington's program

## Summary
- Takeda notified Wave it will not exercise option for HTT target, ending collaboration; Takeda previously paid ~$260M to Wave.
- Wave regains full rights to WVE-003 and all HTT-targeting programs, with potential $5B-$10B commercial opportunity.
- SELECT-HD clinical trial data generated significant interest from prospective partners for WVE-003.
- Wave expects regulatory feedback on accelerated approval pathway for WVE-003 by end of 2024.
- Cash runway unchanged into 2027, excluding potential GSK milestones.

## SEC filing metadata
- accession: 0001193125-24-237665
- form_type: 8-K
- ticker: WVE
- cik: 0001631574
- company_name: Wave Life Sciences Ltd.
- filed_at: 2024-10-15T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 7.01, 8.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1631574/000119312524237665/0001193125-24-237665-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1631574/000119312524237665/d899308d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-24-237665
- JSON: https://secwatch.observer/filing/0001193125-24-237665.json
- Plain text: https://secwatch.observer/filing/0001193125-24-237665.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.